References
- Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Hear Lung Transplant 2015;34(12):1495–1504. doi:https://doi.org/10.1016/j.healun.2015.10.003.
- Potapov EV, Antonides C, Crespo-Leiro MG, et al. EACTS expert consensus on long-term mechanical circulatory support. Eur J Cardio-thoracic Surg 2019;2019(56):230–270.
- Gustafsson F, Shaw S, Lavee J, Saeed D, Pya Y, Krabatsch T, Schmitto J, Morshuis M, Chuang J, Damme L, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. Eur Heart J 2018;39(37):3454–3460. doi:https://doi.org/10.1093/eurheartj/ehy513.
- Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 2017;376(5):451–460. doi:https://doi.org/10.1056/NEJMoa1602954.
- Mehra MR, Uriel N, Naka Y, Cleveland JC, Yuzefpolskaya M, Salerno CT, Walsh MN, Milano CA, Patel CB, Hutchins SW, et al. A fully magnetically levitated left ventricular assist device - Final report. N Engl J Med 2019;380(17):1618–1627. doi:https://doi.org/10.1056/NEJMoa1900486.
- Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM, Long JW, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361(23):2241–2251. doi:https://doi.org/10.1056/NEJMoa0909938.
- Milano CA, Rogers JG, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Mokadam NA, Mahr C, Miller JS, Markham DW, et al. HVAD: the ENDURANCE supplemental trial. JACC Heart Fail 2018;6(9):792–802. doi:https://doi.org/10.1016/j.jchf.2018.05.012.
- Schramm R, Zittermann A, Morshuis M, Schoenbrodt M, Roessing E, Dossow V, Koster A, Fox H, Hakim‐Meibodi K, Gummert JF, et al. Comparing short‐term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®. ESC Hear Fail 2020;7(3):908–914. doi:https://doi.org/10.1002/ehf2.12649.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C, et al. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014;111(3):474–482. doi:https://doi.org/10.1160/TH13-07-0558.
- Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104(13):1533–1537. doi:https://doi.org/10.1161/hc3801.095588.
- Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961–965. doi:https://doi.org/10.1016/S0735-1097(02)03014-0.
- Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53(10):849–856. doi:https://doi.org/10.1016/j.jacc.2008.11.030.
- Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schömig A, Von Beckerath N, Kastrati A, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8(2):250–256. doi:https://doi.org/10.1111/j.1538-7836.2009.03709.x.
- Gremmel T, Xhelili E, Steiner S, Koppensteiner R, Kopp CW, Panzer S, et al. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty. Atherosclerosis 2014;232(1):119–124. doi:https://doi.org/10.1016/j.atherosclerosis.2013.10.027.
- Wadowski PP, Weikert C, Pultar J, Lee S, Eichelberger B, Koppensteiner R, Lang IM, Panzer S, Gremmel T, et al. Ticagrelor inhibits toll-like and protease-activated receptor mediated platelet activation in acute coronary syndromes. Cardiovasc Drugs Ther 2020;34(1):53–63. doi:https://doi.org/10.1007/s10557-019-06932-7.
- Gremmel T, Koppensteiner R, Panzer S. Comparison of aggregometry with flow cytometry for the assessment of agonists’-induced platelet reactivity in patients on dual antiplatelet therapy. PLoS One 2015;10:e0129666. doihttps://doi.org/10.1371/journal.pone.0129666.
- Gremmel T, Kopp CW, Seidinger D, Giurgea G-A, Koppensteiner R, Steiner S, Panzer S, et al. The formation of monocyte–platelet aggregates is independent of on-treatment residual agonists’-inducible platelet reactivity. Atherosclerosis 2009;207(2):608–613. doi:https://doi.org/10.1016/j.atherosclerosis.2009.05.037.
- Gremmel T, Calatzis A, Steiner S, Kaider A, Seidinger D, Koppensteiner R, Kopp CW, Panzer S, et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets 2010;21(7):515–521. doi:https://doi.org/10.3109/09537104.2010.493587.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW, et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011;22(3):188–195. doi:https://doi.org/10.3109/09537104.2010.543963.
- Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW, et al. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Transl Res 2013;161(5):421–429. doi:https://doi.org/10.1016/j.trsl.2012.12.015.
- Patzke J, Budde U, Huber A, Méndez A, Muth H, Obser T, Peerschke E, Wilkens M, Schneppenheim R, et al. Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin. Blood Coagul Fibrinolysis 2014;25(8):860–870. doi:https://doi.org/10.1097/MBC.0000000000000169.
- Gremmel T, Kopp CW, Steiner S, Seidinger D, Ay C, Koppensteiner R, Mannhalter C, Panzer S, et al. The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. Atherosclerosis [Internet]. 2011;217(1):135–138. Available from: https://pubmed-ncbi-nlm-nih-gov.ez.srv.meduniwien.ac.at/21497813/
- Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56(12):919–933. doi:https://doi.org/10.1016/j.jacc.2010.04.047.
- Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz K-L, et al. Aspirin treatment and outcomes after percutaneous coronary intervention. J Am Coll Cardiol 2014;64(9):863–871. doi:https://doi.org/10.1016/j.jacc.2014.05.049.
- Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet J-P, Cuisset T, Franchi F, Gross L, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019;12(16):1521–1537. doi:https://doi.org/10.1016/j.jcin.2019.03.034.
- Totani L, Platelet–Leukocyte EV. Interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010;30:2357–2361. doihttps://doi.org/10.1161/ATVBAHA.110.207480.
- Gremmel T, Koppensteiner R, Kaider A, Eichelberger B, Mannhalter C, Panzer S, et al. Impact of variables of the P-selectin – p-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb Haemost 2015;113:806–812. doi:https://doi.org/10.1160/TH14-08-0690.
- Gremmel T, Ay C, Riedl J, Kopp CW, Eichelberger B, Koppensteiner R, Panzer S, et al. Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thromb Haemost 2016;115(3):615–621. doi:https://doi.org/10.1160/th15-07-0598.
- Shattil SJ, Hoxie JA, Cunningham M, Brass LF, et al. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985;260:11107–11114. doi:https://doi.org/10.1016/S0021-9258(17)39154-8.
- Consolo F, Sferrazza G, Motolone G, Contri R, Valerio L, Lembo R, Pozzi L, Della Valle P, De Bonis M, Zangrillo A, et al. Platelet activation is a preoperative risk factor for the development of thromboembolic complications in patients with continuous-flow left ventricular assist device. Eur J Heart Fail 2018;20(4):792–800. doi:https://doi.org/10.1002/ejhf.1113.
- Geisen U, Brehm K, Trummer G, Berchtold-Herz M, Heilmann C, Beyersdorf F, Schelling J, Schlagenhauf A, Zieger B, et al. Platelet secretion defects and Acquired von Willebrand syndrome in patients with ventricular assist devices. J Am Heart Assoc 2018;7(2):7. doi:https://doi.org/10.1161/JAHA.117.006519.
- Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE, Gawaz M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27(20):2420–2425. doi:https://doi.org/10.1093/eurheartj/ehl275.
- Pedersen SB, Grove EL, Nielsen HL, Mortensen J, Kristensen SD, Hvas A-M, et al. Evaluation of aspirin response by Multiplate® whole blood aggregometry and light transmission aggregometry. Platelets 2009;20(6):415–420. doi:https://doi.org/10.1080/09537100903100643.
- Steinlechner B, Dworschak M, Birkenberg B, Duris M, Zeidler P, Fischer H, Milosevic L, Wieselthaler G, Wolner E, Quehenberger P, et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg 2009;87(1):131–137. doi:https://doi.org/10.1016/j.athoracsur.2008.10.027.
- Baghai M, Heilmann C, Beyersdorf F, et al. Platelet dysfunction and acquired vonWillebrand syndrome in patients with left ventricular assist devices. Eur J Cardio-thoracic Surg 2015;48:421–427.
- Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB, et al. Severely impaired von willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009;53(23):2162–2167. doi:https://doi.org/10.1016/j.jacc.2009.02.048.
- Bansal A, Uriel N, Colombo PC, Narisetty K, Long JW, Bhimaraj A, Cleveland JC, Goldstein DJ, Stulak JM, Najjar SS, et al. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: a prospective multicenter clinical trial. J Hear Lung Transplant 2019;38(8):806–816. doi:https://doi.org/10.1016/j.healun.2019.05.006.
- Meyer AL, Malehsa D, Budde U, et al. Acquired von willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. J Am Coll Cardiol HF 2014;2:141–145.
- Patrono C, García Rodríguez LA, Landolfi R, Baigent C, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353(22):2373–2383. doi:https://doi.org/10.1056/NEJMra052717.
- Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. J Am Coll Cardiol [Internet]. 2009;53(8):667–677. Available from: https://pubmed.ncbi.nlm.nih.gov/19232899/